(firstQuint)A Study to Investigate ICP-022 in Chinese Patients With R/R Mantle Cell Lymphoma (MCL).

 Part I: PK/PD and safety evaluation -Two regimens of ICP-022 (High dose QD and low dose BID) were designed for assessment of safety, as well as PK/PD profiles.

 The recommended dose of phase II clinical study will be determined according to the Part I results.

 Part II: Dose expansion -Anti-tumor effects of ICP-022 in Chinese patients with R/R MCL will be evaluated in approximately 80 subjects.

 The recommended Phase 2 dose will be used in the Part II.

.

 A Study to Investigate ICP-022 in Chinese Patients With R/R Mantle Cell Lymphoma (MCL)@highlight

The phase I/II clinical study is to investigate the safety, tolerability and pharmacokinetics/ pharmacodynamics of ICP-022.

